Trial reportMolecular imaging and biology2016
Biodistribution and Radiation Dosimetry of the Enterobacteriaceae-Specific Imaging Probe [(18)F]Fluorodeoxysorbitol Determined by PET/CT in Healthy Human Volunteers.
Trial report in Molecular imaging and biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Biodistribution and dosimetry ofMedical physics · 2025Article
- Observational
- Biorecognition-Based Nanodiagnostics: Maltotriose-Functionalized Magnetic Nanoparticles for Targeted Magnetic Resonance Imaging of Bacterial Infections.Bioengineering (Basel, Switzerland) · 2025Article
- Imaging quantitative changes in blood-brain barrier permeability using [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Article
- PET/CT Imaging of Infectious Diseases: Overview of Novel Radiopharmaceuticals.Diagnostics (Basel, Switzerland) · 2024Review
- Assessing the applicability of PMOD residence times model for PET image-based radiation dosimetry.Scientific reports · 2023Article
- Imaging Diverse Pathogenic Bacteria In Vivo withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Infection-specific PET imaging withFrontiers in microbiology · 2023Article
- Imaging joint infections using D-methyl-European journal of nuclear medicine and molecular imaging · 2022Article
- In vivo imaging of invasive aspergillosis withNature communications · 2022Article
- [Pharmaceutics · 2021Article
- ImagingScience translational medicine · 2021Article
- An easy and practical guide for imaging infection/inflammation by [Clinical and translational imaging · 2021Review
- Nuclear Imaging of Bacterial Infection: The State of the Art and Future Directions.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Review
- Radiotracer Development for Bacterial Imaging.Journal of medicinal chemistry · 2020Review
- Molecular Imaging of Diabetic Foot Infections: New Tools for Old Questions.International journal of molecular sciences · 2019Review
- Pathogen-Specific Bacterial Imaging in Nuclear Medicine.Seminars in nuclear medicine · 2018Review
- The Promise of Molecular Imaging in the Study and Treatment of Infectious Diseases.Molecular imaging and biology · 2017Review
- A Systematic Approach for Developing Bacteria-Specific Imaging Tracers.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose[(18)F]fluorodeoxysorbitol ([(18)F]FDS) is the first radiopharmaceutical specific for a category of bacteria and has the potential to specifically detect Enterobacteriaceae infections. The purpose of this study was to testify the safety and investigate the biodistribution and radiation dosimetry of [(18)F]FDS in healthy human bodies. PROCEDURES: Six healthy subjects were intravenously injected with 320-520 MBq [(18)F]FDS. On each subject, 21 whole-body emission scans and a brain scan were conducted at settled time points within the next 4 h. Residence time for each source organ was determined by multi-exponential regression. Absorbed doses for target organs and effective dose were calculated via OLINDA/EXM.
resultsNo adverse events due to [(18)F]FDS injection were observed in the study. The tracer was cleared rapidly from the blood pool through the urinary system. A small portion was cleared into the gut through the hepatobiliary system. The effective dose (ED) was estimated to be 0.021 ± 0.001 mSv/MBq. The organ receiving the highest absorbed dose was the urinary bladder wall (0.25 ± 0.03 mSv/MBq).
conclusions[(18)F]FDS is safe and well tolerated. The effective dose was comparable to that of other F-18 labeled radiotracers. [(18)F]FDS is suitable for human use from a radiation dosimetry perspective.
Indexed as
Identifiers
27020679What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.